ArticleDigestive diseases and sciences1997
Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease.
Article in Digestive diseases and sciences, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03644966 (Probiotic and Effects on Multi-Drug Resistant Urinary Tract Infection), which is not on this map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Probiotic and Effects on Multi-Drug Resistant Urinary Tract Infection
Who cites it
47 citing papers in PubMed, 222 citations in OpenAlex.
- Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet.World journal of gastroenterology · 2010Trial
- Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission.Digestive diseases and sciences · 2002Trial
- Research progress on the use of polyphenols in the treatment of Crohn's disease.Frontiers in pharmacology · 2025Review
- Article
- Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin.Frontiers in microbiology · 2022Review
- Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease.Frontiers in medicine · 2022Review
- Quality of Life in Inflammatory Bowel Diseases (IBDs) Patients after Surgery.Reviews on recent clinical trials · 2022Review
- Impact of Microbial Metabolites on Microbiota-Gut-Brain Axis in Inflammatory Bowel Disease.International journal of molecular sciences · 2021Review
- Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease.Frontiers in physiology · 2021Review
- Connection between the Gut Microbiome, Systemic Inflammation, Gut Permeability and FOXP3 Expression in Patients with Primary Sjögren's Syndrome.International journal of molecular sciences · 2020Article
- Bifidobacterium breve UCC2003 Induces a Distinct Global Transcriptomic Program in Neonatal Murine Intestinal Epithelial Cells.iScience · 2020Article
- Impacts of foodborne inorganic nanoparticles on the gut microbiota-immune axis: potential consequences for host health.Particle and fibre toxicology · 2020Review
- Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome.Pathogens (Basel, Switzerland) · 2019Review
- Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.Arthritis research & therapy · 2017Article
- Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis.Immunology · 2015Review
- Gut Microbial Dysbiosis Due to Helicobacter Drives an Increase in Marginal Zone B Cells in the Absence of IL-10 Signaling in Macrophages.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Article
- Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis.World journal of gastroenterology · 2014Review
- Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective.Cellular and molecular life sciences : CMLS · 2014Review
- Nutritional protective mechanisms against gut inflammation.The Journal of nutritional biochemistry · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digestive bacterial microflora play a major role in the pathogenesis of Crohn's disease (CD). Bacterial enzyme activities, especially beta-D-galactosidase, are decreased in fecal extracts from CD patients. We hypothesized that an alteration of the colonic flora might be responsible for this decrease. Indeed, we demonstrate that beta-D-galactosidase production in supernates of anaerobic cultures was significantly (P < 0.01) reduced in feces from patients with active Crohn's disease (N = 7), when compared to healthy controls (N = 8). Therefore using X-gal and selective media, we enumerated bacteria able to release beta-D-galactosidase in feces from patients with active (N = 16) or quiescent disease (N = 5) and healthy controls (N = 14). Bifidobacteria numbers were significantly reduced in patients (P < 0.01 for active; P < 0.02 for quiescent disease) whereas Bacteroides and Lactobacilli counts remained unchanged. beta-D-Galactosidase activity and Bifidobacteria counts were significantly correlated (P < 0.03). Bifidobacteria are regarded as beneficial for the host. The reduction in Bifidobacteria is responsible for decreased beta-D-galactosidase activity. Thus oral administration of prebiotics that promote their growth might have potential therapeutic interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.